Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi-Aventis Cuts U.S. Sales Staff

by Lisa M. Jarvis
October 18, 2010 | A version of this story appeared in Volume 88, Issue 42

With generic-drug competition for its blood thinner Plavix around the corner, Sanofi-Aventis is cutting 25% of its U.S. pharmaceutical operations division, or about 1,700 sales positions, as part of a restructuring of the division. Furthermore, the U.S. pharma division will now focus solely on diabetes, atrial fibrillation, and oncology. About 13,000 people work for Sanofi in the U.S., 6,900 of whom are in the pharmaceutical operations division. Plavix, one of Sanofi’s top-selling drugs, with sales totaling $3.6 billion in 2009, is set to lose U.S. patent protection in 2012.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.